Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Heart Test Laboratories, Inc. - Common Stock (NQ: HSCS ) 3.400 -0.080 (-2.30%) Streaming Delayed Price Updated: 11:53 AM EDT, Aug 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Heart Test Laboratories, Inc. - Common Stock < Previous 1 2 Next > HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results July 29, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency July 26, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare July 25, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction July 11, 2024 Further expands HeartSciences extensive patent portfolio From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Regains Compliance with Nasdaq Listing Requirements June 04, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio May 20, 2024 Granted Indian Patent for its MyoVista® Wavelet Technology From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG April 24, 2024 Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences to Present at the LD Micro Invitational XIV Conference April 02, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients March 26, 2024 Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Reports Third Quarter Fiscal 2024 Financial Results March 14, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes March 12, 2024 Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and ARIC HF score, the conventional standards of care for Stage B Heart Failure screening From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology March 06, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Adds Key Advisor to its Scientific Advisory Board February 26, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Expands its Scientific Advisory Board February 12, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Appoints New Scientific Advisory Board Member February 01, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting January 18, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting January 03, 2024 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Reports Second Quarter Fiscal 2024 Financial Results December 14, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway December 05, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms November 20, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers November 13, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio September 26, 2023 Patents Cover MyoVista® Wavelet Technology Utilizing AI for Early Detection of Heart Disease From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I. September 25, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms September 21, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Reports First Quarter Fiscal 2024 Financial Results September 14, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase September 12, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards September 11, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India September 07, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences Signs Distribution Agreement with FJ Medical, Denmark August 31, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire HeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation August 24, 2023 From Heart Test Laboratories, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.